Trials / Completed
CompletedNCT01625988
A Study of LY2951742 in Participants With Migraine
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 218 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in migraineurs with or without aura during 3 months of treatment.
Detailed description
The study is comprised of 4 trial periods: 1. Screening and washout (5-45 days) 2. Baseline for assessment of the type, frequency, and severity of headaches (28-38 days) 3. Treatment (12 weeks) 4. Follow-up (12 weeks)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2951742 | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-06-28
- Primary completion
- 2013-07-01
- Completion
- 2013-09-18
- First posted
- 2012-06-22
- Last updated
- 2020-01-09
- Results posted
- 2020-01-09
Locations
37 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01625988. Inclusion in this directory is not an endorsement.